Literature DB >> 33534213

Pure and Mixed Desmoplastic Melanomas: A Retrospective Clinicopathologic Comparison of 33 Cases.

Sherman Chu1,2, Kory P Schrom3, Raghav Tripathi1, Rosalynn R Z Conic4, Harib H Ezaldein1,3, Jeffrey F Scott1,3,5, Kord Honda1,3.   

Abstract

BACKGROUND: Pure and mixed desmoplastic melanomas (DMs) may have different natural histories and behaviors.
METHODS: We conducted a retrospective review of patients diagnosed with DM at our institution between January 1997 and April 2019. A total of 33 unique DMs were identified and subsequently analyzed based on the histologic type (pure vs. mixed).
RESULTS: The majority (57.6%) of our cases were classified as pure histology. Patients with pure DMs were more likely to be men (P = 0.035) and be older than 65 years (P = 0.019) compared with patients with mixed DMs. Patients with mixed DM were more likely to have mitoses present (P = 0.001) compared with patients with pure DM. There were no differences in ulceration, perineural invasion, vascular invasion, or survival between patients with pure and mixed histologic subtypes. In addition, no differences in sentinel lymph node biopsy, radiation, or chemotherapy were noted between the 2 histologic subtypes. Immunohistochemistry showed that 27.3% of the pure DMs stained with Melan-A and HMB45 were positive for these immunomarkers.
CONCLUSIONS: Pure and mixed variants of DM were found to have similar clinicopathologic characteristics. Patients with the mixed histologic subtype were more likely to have mitoses, but no difference in the therapeutic management or patient survival was seen between the 2 subtypes.
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33534213      PMCID: PMC8310890          DOI: 10.1097/DAD.0000000000001909

Source DB:  PubMed          Journal:  Am J Dermatopathol        ISSN: 0193-1091            Impact factor:   1.319


  30 in total

Review 1.  Desmoplastic melanoma: an updated clinical review and the emerging role of genetic markers and immunotherapies.

Authors:  Matthew J Hadfield; Racquel Helsing; Jane M Grant-Kels
Journal:  Melanoma Res       Date:  2020-10       Impact factor: 3.599

2.  Case of desmoplastic melanoma with lung metastasis maintaining complete response after cessation of nivolumab.

Authors:  Azusa Murayama; Munenari Itoh; Keigo Ito; Katsumi Tanito; Katsuhiro Ishida; Yoshimasa Nobeyama; Hidemi Nakagawa
Journal:  J Dermatol       Date:  2016-07-27       Impact factor: 4.005

Review 3.  Is sentinel lymph node biopsy warranted for desmoplastic melanoma? A systematic review.

Authors:  Jonathan A Dunne; Justin C R Wormald; Jessica Steele; Elizabeth Woods; Joy Odili; Barry W E M Powell
Journal:  J Plast Reconstr Aesthet Surg       Date:  2016-11-16       Impact factor: 2.740

4.  Desmoplastic melanoma: is there a role for sentinel lymph node biopsy?

Authors:  Dale Han; Jonathan S Zager; Daohai Yu; Xiuhua Zhao; Brooke Walls; Suroosh S Marzban; Nikhil G Rao; Vernon K Sondak; Jane L Messina
Journal:  Ann Surg Oncol       Date:  2013-02-07       Impact factor: 5.344

5.  Clinical and dermoscopic characteristics of desmoplastic melanomas.

Authors:  Natalia Jaimes; Lucy Chen; Stephen W Dusza; Cristina Carrera; Susana Puig; Luc Thomas; John W Kelly; Lucy Dang; Iris Zalaudek; Ralph P Braun; Scott W Menzies; Klaus J Busam; Ashfaq A Marghoob
Journal:  JAMA Dermatol       Date:  2013-04       Impact factor: 10.282

Review 6.  Desmoplastic melanoma.

Authors:  Norman G Nicolson; Dale Han
Journal:  J Surg Oncol       Date:  2018-11-27       Impact factor: 3.454

7.  Desmoplastic melanoma: a 12-year experience with sentinel lymph node biopsy.

Authors:  P N Broer; M E Walker; C Goldberg; S Buonocore; D T Braddock; R Lazova; D Narayan; S Ariyan
Journal:  Eur J Surg Oncol       Date:  2013-03-22       Impact factor: 4.424

8.  Subclassification of desmoplastic melanoma: pure and mixed variants have significantly different capacities for lymph node metastasis.

Authors:  Evan George; Susannah E McClain; Craig L Slingluff; Nayak L Polissar; James W Patterson
Journal:  J Cutan Pathol       Date:  2009-04       Impact factor: 1.587

Review 9.  Desmoplastic melanoma: recent advances and persisting challenges.

Authors:  Benjamin A Wood
Journal:  Pathology       Date:  2013-08       Impact factor: 5.306

10.  High response rate to PD-1 blockade in desmoplastic melanomas.

Authors:  Zeynep Eroglu; Jesse M Zaretsky; Siwen Hu-Lieskovan; Dae Won Kim; Alain Algazi; Douglas B Johnson; Elizabeth Liniker; Rodrigo Munhoz; Suthee Rapisuwon; Pier Federico Gherardini; Bartosz Chmielowski; Xiaoyan Wang; I Peter Shintaku; Cody Wei; Jeffrey A Sosman; Richard W Joseph; Michael A Postow; Matteo S Carlino; Wen-Jen Hwu; Richard A Scolyer; Jane Messina; Alistair J Cochran; Georgina V Long; Antoni Ribas
Journal:  Nature       Date:  2018-01-10       Impact factor: 49.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.